Therapeutics News and Research

RSS

BioAlliance Pharma to discuss nanoparticle technology and its therapeutic applications at the French-Norwegian Interdisciplinary Symposium

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter's advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to take place in Bergen, Norway, from August 31 to September 2, 2009.

29 Aug 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).

28 Aug 2009

NAT gains importance as traditional testing methods become inadequate

An expanding population of bacterial strains that are drug resistant, including methicillin-resistant Staphylococcus aureus (MRSA), will be the most important justification for nucleic acid-based tests (NAT).

28 Aug 2009

Springer signs agreement with The Endocrine Society to co-publish a new journal

Springer, one of the leading publishers in the fields of science, technology and medicine, has signed an agreement with The Endocrine Society to co-publish a new journal, Hormones & Cancer, starting in January 2010.

28 Aug 2009

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

Anavex Life Sciences Corp. ("ANAVEX" or the "Company") reports the publication of a comprehensive review of the pharmacology of sigma receptors and their possible clinical application in the peer-reviewed Journal of Pharmacology Therapeutics.

28 Aug 2009

Abbott to partner with Pfizer to develop a companion diagnostic test for non-small cell lung cancer

Abbott announced today that it has entered into an agreement with Pfizer Inc to develop a molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors for the presence of gene rearrangements.

28 Aug 2009

Kamada finalizes agreement for the distribution of its intravenous alpha-1 antitrypsin in the United States

Kamada (TASE:KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has entered into an exclusive agreement with a large US specialty pharmaceutical distributor company for the distribution of its flagship product, intravenous alpha-1 antitrypsin (AAT-IV) in the United States.

28 Aug 2009

NIMH grants Xhale $1.7 million to develop the SMART medication adherence system for HIV/AIDS therapies

Xhale, Inc. has been awarded a $1.7 million Small Business Innovation Research (SBIR) Phase II grant by the NIH National Institute of Mental Health (NIMH) to continue the development of SMART (Self Monitoring and Reporting Therapeutics), a breath-based medication adherence system for HIV/AIDS therapies.

28 Aug 2009

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.

28 Aug 2009

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the dosing of the first patient in a Phase I clinical study of AR-12 (formerly OSU-03012) in adult patients with advanced or recurrent solid tumors or lymphoma.

28 Aug 2009

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

Geron Corporation today provided additional comments on the recent clinical hold on its Spinal Cord Injury IND.

27 Aug 2009

Waters exhibits the SYNAPT G2 system at the 18th International Mass Spectrometry Conference in Europe

Waters Corporation (NYSE: WAT) today exhibited for the first time in Europe the Waters((R)) SYNAPT(TM) G2 a system offering scientists greater power, versatility and speed at the 18(th) International Mass Spectrometry Conference (IMSC). Rounding out its display of mass spectrometry (MS) and UltraPerformance Liquid Chromatography (UPLC((R)))/MS systems at IMSC will be Waters Xevo(TM) family of tandem quadrupole and time-of-flight mass spectrometers noted for their ease-of-use and versatility.

27 Aug 2009

Study reveals that asthma patients fare better by taking oral controllers than inhaled corticosteroids

Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that asthma patients in general had better clinical outcomes with oral controllers than inhaled corticosteroids.

27 Aug 2009

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

Merck & Co., Inc., Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme Limited, announced today that the European Medicines Agency (EMEA) accepted for review the Company’s Marketing Authorisation Application (MAA) for regulatory approval of vernakalant intravenous (IV).

27 Aug 2009

GI Dynamics to present additional results of mechanisms of actions clinical study

GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced that additional results from a previously reported clinical study regarding mechanisms of action will be presented on Saturday, August 29, 2009 by Manoel Galvao Neto, M.D., scientific coordinator, Gastro Obeso Center, Sao Paulo, Brazil and lead investigator for the study, at the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) 14th World Congress in Paris, France.

27 Aug 2009

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.

27 Aug 2009

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.

27 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

EPIX Pharmaceuticals' PRX-00023 Therapeutics CNS program in Phase 2B/3 offered for auction sale

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-00023 Therapeutics Program in Phase 2b/3 will be part of the intellectual property offered for sale at the September 30, 2009 auction.

26 Aug 2009

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that in general had better clinical outcomes with oral controllers than inhaled corticosteroids.

26 Aug 2009

Therapeutics News and Research

BioAlliance Pharma to discuss nanoparticle technology and its therapeutic applications at the French-Norwegian Interdisciplinary Symposium

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

NAT gains importance as traditional testing methods become inadequate

Springer signs agreement with The Endocrine Society to co-publish a new journal

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

Abbott to partner with Pfizer to develop a companion diagnostic test for non-small cell lung cancer

Kamada finalizes agreement for the distribution of its intravenous alpha-1 antitrypsin in the United States

NIMH grants Xhale $1.7 million to develop the SMART medication adherence system for HIV/AIDS therapies

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

Waters exhibits the SYNAPT G2 system at the 18th International Mass Spectrometry Conference in Europe

Study reveals that asthma patients fare better by taking oral controllers than inhaled corticosteroids

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

GI Dynamics to present additional results of mechanisms of actions clinical study

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

EPIX Pharmaceuticals' PRX-00023 Therapeutics CNS program in Phase 2B/3 offered for auction sale

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News